Safety Study of an Oral Vitamin D Analog in Postmenopausal Women

Postmenopausal Osteoporosis, Multiple Sites Clinical Trial

Official title:

A Phase 1B, Double-Blind, Placebo-Controlled, Calcitriol Active-Controlled, Daily-Dose, Escalating-Dose, Safety and Tolerance Study of 2MD Soft Gel Capsules in Normal Healthy Postmenopausal Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01969656
• Other study ID #: 2MD-3H-1B/C
• Status: Completed
• Phase: Phase 1
• First received: October 22, 2013
• Last updated: July 25, 2017

Study information

• Verified date: July 2017
• Source: Deltanoid Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. primary completion date: June 2004
• Gender: Female
• Age group: 45 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Normal healthy postmenopausal women, = 60 but = 80 years of age, or between 45 and 60 years of age who have been amenorrheic for at least 2 years plus have a serum FSH level of > 30 IU/L, or women with a documented bilateral oophorectomy at least 2 years prior to study start.

2. Within ±30% of their ideal body weight for height and body frame.

3. Demonstrated ability to understand and willingness to sign an Informed Consent Form.

4. 24-hour urinary Ca =250 mg/day and a urinary Ca:Cr =0.35.

5. Negative urine test for selected drugs of abuse.

6. Willing to maintain a total calcium intake between 700 and 1000 mg/day.

Exclusion Criteria:

1. Any acute or chronic condition that would limit the subject's ability to complete the study.

2. Active clinical manifestations of significant metabolic, hematological, pulmonary, hepatic, cardiovascular, gastrointestinal (including malabsorption), neurological, renal, urological or psychiatric disorders.

3. History or presence of any diseases known or believed to influence calcium absorption or metabolism.

4. History of renal calculi.

5. History of an eating disorder.

6. History of stomach or intestinal surgery.

7. History of hypersensitivity or allergies to any vitamin D derivative.

8. History or presence of an abnormal ECG.

9. Use of any medications or products affecting vitamin D metabolism within 6 months prior to study entry.

10. Use of any medications or products affecting calcium balance or bone turnover within 6 months prior to study entry.

11. Participation in any other investigational study drug trial in which receipt of investigational study drug occurred within 60 days prior to study entry.

12. Use of vitamin and/or mineral supplements >1X RDI within 4 weeks prior to study entry, unless deemed acceptable by Investigator.

13. Poor peripheral venous access.

14. Receipt of blood products within 2 months prior to study entry.

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Postmenopausal
• Postmenopausal Osteoporosis, Multiple Sites

Intervention

Drug:
• 2MD

• Calcitriol

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Deltanoid Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in total serum calcium		Days 0 (pre-dose), 1, 2, 3, 7, 14, 21, 27, 28 and 2 weeks after last dose
Primary	Change from baseline in levels of 2MD in the blood		1, 2, 3, 12, 18 and 24 h after the initial dose on Day 0 and after the final dose on Day 27